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RESEARCH ARTICLE Open Access
Packed red blood cell transfusion
associates with acute kidney injury after
transcatheter aortic valve replacement
Akeel M. Merchant1, Javier A. Neyra2,3,4, Abu Minhajuddin5, Lauren E. Wehrmann1, Richard A. Mills6,
Sarah K. Gualano7, Dharam J. Kumbhani7, Lynn C. Huffman8, Michael E. Jessen8 and Amanda A. Fox1,9*
Abstract
Background: Acute kidney injury after cardiac surgery significantly associates with morbidity and mortality. Despite
not requiring cardiopulmonary bypass, transcatheter aortic valve replacement patients have an incidence of post-
procedural acute kidney injury similar to patients who undergo open surgical aortic valve replacement. Packed red
blood cell transfusion has been associated with morbidity and mortality after cardiac surgery. We hypothesized that
packed red blood cell transfusion independently associates with acute kidney injury after transcatheter aortic valve
replacement, after accounting for other risk factors.
Methods: This is a single-center retrospective cohort study of 116 patients undergoing transcatheter aortic valve
replacement. Post-transcatheter aortic valve replacement acute kidney injury was defined by Kidney Disease:
Improving Global Outcomes serum creatinine-based criteria. Univariate comparisons between patients with and
without post-transcatheter aortic valve replacement acute kidney injury were made for clinical characteristics.
Multivariable logistic regression was used to assess independent association of packed red blood cell transfusion
with post-transcatheter aortic valve replacement acute kidney injury (adjusting for pre-procedural renal function
and other important clinical parameters).
Results: Acute kidney injury occurred in 20 (17.2%) subjects. Total number of packed red blood cells transfused
independently associated with post-procedure acute kidney injury (OR = 1.67 per unit, 95% CI 1.13–2.47, P = 0.01)
after adjusting for pre-procedure estimated glomerular filtration rate (OR = 0.97 per ml/min/1.73m2, 95% CI 0.94–
1.00, P = 0.05), nadir hemoglobin (OR = 0.88 per g/dL increase, CI 0.61–1.27, P = 0.50), and post-procedure maximum
number of concurrent inotropes and vasopressors (OR = 2.09 per inotrope or vasopressor, 95% CI 1.19–3.67, P =
0.01).
Conclusion: Packed red blood cell transfusion, along with post-procedure use of inotropes and vasopressors,
independently associate with acute kidney injury after transcatheter aortic valve replacement. Further studies are
needed to elucidate the pathobiology underlying these associations.
Keywords: Blood cell transfusion, Acute kidney injury, Transcatheter aortic valve replacement, Vasoconstrictor
agents, Anemia
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Introduction
Aortic stenosis is a common form of degenerative valve
disease and its prevalence markedly increases as people
age [1, 2]. Many patients with aortic stenosis have comor-
bidities that place them at higher risk for morbidity and
mortality after surgical aortic valve replacement (SAVR).
As a consequence, trans-catheter aortic valve replacement
(TAVR) has been increasingly utilized as an alternative to
SAVR for aortic valve replacement in patients who are
intermediate or high risk SAVR candidates. Despite being
less invasive than SAVR and not requiring cardiopulmo-
nary bypass (CPB), the risk of TAVR patients developing
post-procedure AKI is similar to the risk observed in
SAVR patients (~ 10–30%) [3–6]. The occurrence of AKI
is associated with increased morbidity and mortality in
both SAVR and TAVR patients [3, 7–10]. It is therefore
important to identify perioperative risk factors that are po-
tentially modifiable for AKI prevention.
Various clinical risk factors have been associated in ob-
servational studies with the development of AKI after
TAVR [3, 9–14]. These have included clinical variables
such as chronic kidney disease, trans-apical TAVR ap-
proach, diabetes, hypertension, peripheral vascular dis-
ease, chronic obstructive pulmonary disease, history of
myocardial infarction, leukocytosis, bleeding, and blood
transfusion [3, 9–14]. Interestingly, a meta-analysis of
observational studies reported that contrast media vol-
ume is not significantly associated with development of
AKI after TAVR [15].
Transfusion of packed red blood cells (pRBCs) during
cardiac surgery or TAVR may be avoided depending
upon clinical management of factors such as preopera-
tive anemia, perioperative fluid administration, and uti-
lized transfusion thresholds. In cardiac surgical patients,
pRBC transfusion has been associated with development
of AKI, with perioperative anemia seeming to present an
additional additive risk [16–18]. Observational cohort
studies examining the association between pRBC trans-
fusion and the development of AKI after TAVR have re-
ported conflicting results [11, 12, 19]. To date, the studies
that have assessed the association between pRBC transfu-
sion and AKI after TAVR have not included peri-procedure
anemia, fluid balance, intra-procedure hypotension, and
intra-procedure and post-procedure inotrope/vasopressor
use as potential confounders. Since lower nadir hemoglobin
(Hgb), hypotension and need for inotropes or vasopressor
drugs may occur in conjunction with bleeding and need for
blood transfusion, it is important to assess these factors
along with pRBC transfusion in order to identify what risk
factors might best be targeted to prevent AKI after TAVR.
Given the potential inter-relations between peri-
procedure pRBC transfusion, fluid balance, anemia,
hypotension and vasoactive drug administration, this
study aimed to assess if pRBC transfusion as well as
these other potential risk factors associate with the de-
velopment of AKI after TAVR. The primary hypothesis
of this study is that pRBC transfusion associates with
AKI after TAVR even after adjusting for other clinical
parameters such as peri-procedure anemia and the use
of vasoactive drugs.
Materials and methods
Study population
This retrospective single-center cohort study assessed
116 patients who underwent consecutive TAVRs at the
University of Texas Southwestern (UTSW) Medical
Center from March 20, 2013 to May 11, 2016. The study
was approved by the UTSW Institutional Review Board
(IRB), and need for patient written informed study con-
sent was waived by the IRB given that this study in-
volved retrospective review of electronic health records
(EHRs). Of the 123 patients who underwent TAVR dur-
ing the study time period, 6 patients were excluded from
analysis because of pre-procedure end-stage renal dis-
ease, and one patient was excluded from analysis for be-
ing an outlier with regards to need for peri-procedure
pRBC transfusion (i.e. massive transfusion protocol).
Data collection
Patient data regarding demographics, preoperative med-
ical history, TAVR device and approach, and intra-
procedure and in-hospital post-procedure events were
manually extracted from each patient’s electronic health
record using a standardized case report form.
Definitions
The study outcome was the development of AKI within
7 days post-TAVR. Post-TAVR AKI was defined accord-
ing to Kidney Disease: Improving Global Outcomes
(KDIGO) serum creatinine (SCr)-based criteria (i.e. SCr
increase by ≥0.3 mg/dl within 48 h after TAVR or an in-
crease in SCr to ≥1.5 times pre-TAVR SCr within the 7
days following TAVR) [20]. Pre-TAVR SCr was defined
as the SCr measured before and closest to the time of
TAVR procedure. Post-TAVR SCr values were compared
with the pre-TAVR SCr for purposes of identifying post-
TAVR AKI. Post-TAVR SCr values were evaluated
through 7 days after TAVR or until hospital discharge if
that occurred earlier than 7 days after TAVR.
Need for pRBC transfusion was assessed during the
intra-procedure period and during the first 24 h after
TAVR (i.e. peri-procedure pRBC transfusion). Transfusion
of other blood products such as fresh frozen plasma,
platelets, and cryoprecipitate during TAVR and within the
first 24 h post-TAVR were also recorded.
Diabetes was defined as requiring insulin or oral
agents. Estimated glomerular filtration rate (eGFR) was
defined according to the Modification of Diet in Renal
Merchant et al. BMC Anesthesiology           (2019) 19:99 Page 2 of 10
Disease (MDRD) 4 variable equation [21]. Pre-TAVR
European System for Cardiac Operative Risk Evaluation
(EuroSCORE) II mortality risk was retrospectively calcu-
lated by entering clinical data available in the medical
record into the calculator found at http://www.euro-
score.org/calc.html [22–24]. TAVR procedure duration
was defined as minutes between time of vascular access
(skin puncture) and the time of post-procedure dressing
placement. Type of TAVR device implanted was defined
as Generation 1 (Edwards Sapien), Generation 2 (Ed-
wards Sapien XT or Medtronic CoreValve), and Gener-
ation 3 (Edwards Sapien S3 or Medtronic CoreValve
Evolut).
Pre-procedural anemia was defined by the World
Health Organization definition of anemia: hemoglobin
(Hgb) < 12 g/dL for women and Hgb < 13 g/dL for men
[25]. Nadir Hgb was defined as the lowest Hgb measured
as part of routine clinical care during the TAVR proced-
ure or during the first 24 h after TAVR.
Subjects were recorded as being on a preoperative
medication if the medication appeared on their pre-
operative medication list in the electronic medical rec-
ord. Data regarding timing of last dose before TAVR
procedure was not fully available from retrospective re-
view. However, at our institution patients generally do
not take angiotensin converting enzyme-inhibitor (ACE-
inhibitor) or angiotensin receptor blocker medications
during the 24 h before TAVR. Patients generally receive
their beta-blocker medication during the 24 h before
TAVR.
Maximum number of concurrent inotropes or vasopres-
sor drugs administered was assessed separately for the
intra-procedure period and the post-procedure period, as
need for transient vasopressor support during the intra-
procedure period is not uncommon secondary to vasodila-
tion under anesthesia as well as to facilitate recovery from
transiently low cardiac output during valve deployment.
However, need for post-TAVR inotrope and vasopressor
drugs was prospectively considered by the investigators to
represent a persistent need for inotropes and vasopressor
drugs that might have greater impact on renal perfusion.
The post-TAVR period for which administration of ino-
trope or vasopressor infusions was assessed included the
first 5 postoperative days or until the patient was dis-
charged from the hospital if that was sooner. Inotropes or
vasopressor drugs included continuous infusions of any of
the following: dobutamine, dopamine, epinephrine, milri-
none, norepinephrine, phenylephrine or vasopressin.
Hypotension during TAVR procedure was defined as
having at least one intra-procedural episode of ≥5 con-
secutive minutes of mean arterial blood pressure
(MAP) < 60 mmHg. Intraoperative hypotension was
assessed for all patients who had continuous blood
pressure monitoring via arterial line that was recorded
minute to minute in the electronic operating room
anesthesia record throughout the TAVR procedure
from before induction of anesthesia to the time of pa-
tient departure from the operating room at the end of
the TAVR procedure. Two patients did not have intra-
operative hypotension data available since their chart-
ing was done on paper with every 5 min blood pressure
noted.
Statistical analysis
Statistical analyses were performed using SAS (version
9.3; SAS Institute, Cary, NC), and all P values were
two-tailed with threshold for significance set at P <
0.05. Table 1 variables were selected a priori to exam-
ine their associations with post-TAVR AKI. Univariate
comparisons between patients who did and did not
develop AKI were made for clinical and procedural
variables using t-tests, Mann-Whitney U tests, Chi-
square tests and Fisher’s Exact tests for continuous
and categorical data, as appropriate. Multivariate lo-
gistic regression was used to assess the association of
pRBC transfusion (independent variable) with post-
TAVR AKI (dependent variable), with adjustments for
pre-procedure estimated glomerular filtration rate
(eGFR) as well as those variables in Table 1 with uni-
variate associations of P < 0.05. Number of pRBCs
transfused and whether patients were transfused any
pRBCs are highly collinear variables, so number of
pRBCs transfused was the variable ultimately included
in the study’s final multivariable model, since this
variable also gives information about transfusion dose.
Results
Demographic, peri-procedural and clinical characteristics
Table 1 describes clinical and procedural characteristics
of the 116 subjects included in the study, with stratifica-
tion according to whether the patient did or did not
develop AKI after TAVR. Twenty subjects (17.2%) devel-
oped AKI after TAVR: 19 developed Stage 1 AKI and
one developed Stage 2 AKI. No patients developed Stage
3 AKI or required dialysis. Subjects had a mean age of
81 years with a SD of 7.5 years, and 55% of subjects were
male. Of the total cohort, 31 subjects (26.7%) were
transfused at least 1 unit of pRBCs in the perioperative
period. Two patients died within 7 days after TAVR, with
one developing AKI prior to death and the other not de-
veloping AKI. Post-TAVR ICU stay was significantly lon-
ger in the post-TAVR AKI group (median 2, IQR 1, 4
days) versus the group that did not develop post-TAVR
AKI (median 2, IQR 1, 2 days) (P = 0.02). Post-TAVR
hospital stay was also significantly greater in the AKI
group (median 5, IQR 3, 12 days) versus the no-AKI
group (median 3, IQR 2, 5 days) (P = 0.01).
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Table 1 Univariate associations between clinical variables and development of acute kidney injury (AKI) after trans-catheter aortic
valve replacement (TAVR)
Clinical Variables No AKI (n =
96)
AKI (n = 20) P
value
Pre-procedure Clinical Characteristics
Age (years) 81 ± 8 83 ± 6 0.28
Female gender 40 (41.7%) 12 (60.0%) 0.13
Ethnicity 0.76
African American 7 (7.3%) 1 (5.0%)
White 72 (75.0%) 14 (70.0%)
Hispanic 11 (11.5%) 4 (20.0%)
Other 6 (6.2%) 1 (5.0%)
Diabetes 33 (34.4%) 5 (25.0%) 0.42
BMI≥ 30 kg/m2 25 (26.0%) 2 (10.0%) 0.15
eGFR (ml/min/1.73m2) 61 ± 20 52 ± 26 0.10
Serum creatinine (mg/dL; median and IQR) 1.09 (0.89,
1.32)
1.21 (1.00,
1.65)
0.16
Anemia 49 (51.0%) 15 (75%) 0.05
Left ventricular ejection fraction (%) (n = 115) 54 ± 12 57 ± 14 0.34
EuroSCORE II (%) (n = 115) 6.34 ± 5.67 7.97 ± 6.81 0.26
Pre-procedure Medications
ACE-inhibitor 40 (41.7%) 8 (40.0%) 0.89
Angiotensin receptor blocker 8 (8.3%) 3 (15.0%) 0.40
Loop diuretic 61 (63.5%) 11 (55.0%) 0.47
Beta blocker 53 (55.2%) 14 (70.0%) 0.22
Statin 74 (77.1%) 12 (60.0%) 0.11
Aspirin 62 (64.6%) 16 (80.0%) 0.18
Procedural Characteristics, Intra- and Post-procedure Events
TAVR approach 0.61
Transfemoral 73 (76.0%) 15 (75.0%)
Transapical 13 (13.5%) 4 (20.0%)
Other 10 (10.5%) 1 (5.0%)
Contrast volume (mL) (n = 115) 103 ± 48 108 ± 54 0.70
Medtronic device (other device Edwards) 32 (33.3%) 5 (25.0%) 0.47
Generation of devicea 0.15
1st generation 26 (27.1%) 9 (45.0%)
2nd generation 44 (45.8%) 9 (45.0%)
3rd generation 26 (27.1%) 2 (10.0%)
Rapid pacing 72 (75.0%) 18 (90.0%) 0.14
General endotracheal anesthesia 92 (95.8%) 20 (100.0%) 0.99
Maximum concurrent number of intra-procedure inotropes/vasopressors 1.6 ± 0.8 1.6 ± 0.7 0.79
Occurrence of at least one intra-procedural hypotensive episode; MAP< 60 mmHg for ≥5 mins (n = 114) 39 (41.1) 8 (42.1) 0.93
Total duration of all intra-procedural hypotensive episodes lasting ≥5 mins (mins) (n = 114) 8.7 ± 17.6 12.2 ± 20.5 0.45
TAVR procedure duration from initial vascular access (skin puncture) to dressing (mins; median and IQR) (n =
111)
115 (97,
144)
133 (105,
180)
0.13
Nadir hemoglobin during procedure and first 24 h post-procedure (g/dL) 9.8 ± 1.7 8.8 ± 1.5 0.02
Total units of pRBC transfusedb 0.4 ± 0.9 1.7 ± 2.4 0.03
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Univariate associations with development of post-TAVR
AKI
Table 1 shows univariate associations between patient
demographic, procedural and clinical variables and the
development of post-TAVR AKI with data stratified
according to whether patients did or did not develop
post-TAVR AKI. Patients who developed post-TAVR
AKI received significantly more pRBC transfusions
than patients who did not (mean units transfused in
AKI group 1.7 versus 0.4 units in no AKI group; P =
0.03; Table 1). Of the patients who developed post-
TAVR AKI, 55% received pRBC transfusion, while
only 21% of the patients who did not develop AKI re-
ceived pRBCs (P = 0.002).
More patients who developed AKI were anemic prior
to TAVR (75% of the AKI group versus 51% of the no
AKI group, P = 0.05). Furthermore, patients who devel-
oped AKI had significantly lower nadir Hgb measure-
ments obtained during the TAVR procedure and the first
24 h following TAVR (mean Hgb 8.8 ± 1.5 g/dL in the
AKI group versus 9.8 ± 1.7 g/dL in the no AKI group;
P = 0.02). Figure 1 shows the patients who did and did
not receive pRBC transfusions and the nadir Hgb re-
corded during TAVR or the 24 h following TAVR for
each patient. Since patients may receive pRBCs in the
setting of ongoing bleeding and need for volume resusci-
tation in the operating room, it is possible that some ac-
tual nadir Hgb was lower than recorded.
Table 1 Univariate associations between clinical variables and development of acute kidney injury (AKI) after trans-catheter aortic
valve replacement (TAVR) (Continued)
Clinical Variables No AKI (n =
96)
AKI (n = 20) P
value
Any pRBC transfusedb 20 (20.8%) 11 (55.0%) 0.002
Any blood product (pRBC, FFP, platelets, cryoprecipitate) transfusedb 21 (21.9%) 11 (55.0%) 0.003
Maximum number of concurrent inotropes/vasopressors administered during post-TAVR hospital stay (up to
end of post-TAVR day 5)
0.5 ± 0.7 1.1 ± 1.2 0.03
Data are shown as n (%) for categorical variables and mean ± standard deviation for continuous variables unless otherwise noted
a generations of TAVR devices defined as Generation 1 (Edwards Sapien), Generation 2 (Edwards Sapien XT or Medtronic CoreValve), and Generation 3 (Edwards
Sapien S3 or Medtronic CoreValve Evolut)
b signifies transfusion during procedure and first 24 h post-TAVR
AKI acute kidney injury, TAVR trans-catheter aortic valve replacement, BMI body mass index, eGFR estimated glomerular filtration rate, ACE angiotensin converting
enzyme, IQR interquartile range, MAP mean arterial pressure, pRBC packed red blood cell, FFP fresh frozen plasma
Fig. 1 Nadir measured hemoglobin (intra-procedure and first 24 h post-TAVR) and number of patients transfused and not transfused pRBCs at
these hemoglobin values. pRBC = packed red blood cells
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Continuous intra-procedure blood pressure monitor-
ing was done via arterial line. Neither the occurrence of
any episode of intraoperative hypotension with MAP <
60mmHg for ≥5 consecutive minutes, the total number
of these intraoperative hypotension episodes, nor the
total number of intraoperative minutes included in these
hypotensive episodes was significantly associated with
development of AKI after TAVR. Having a period of ≥10
consecutive minutes of MAP < 60mmHg was also not
significantly associated with development of post-TAVR
AKI. Intra-procedure rapid pacing was utilized in 90% of
the patients who developed post-TAVR AKI and in 75%
of the patients who did not. This difference was not sta-
tistically significant.
Maximum number of concurrent inotropes and vaso-
pressor drugs utilized during the TAVR procedure did
not differ significantly between the patients who did and
did not develop post-TAVR AKI. However, maximum
number of concurrent inotropes and vasopressor drugs
utilized during the post-TAVR period (up to hospital dis-
charge or through post-procedure day 5) was signifi-
cantly greater in the patients who developed post-TAVR
AKI than in those who did not develop AKI (mean num-
ber of concurrent vasoactive drugs was 1.1 ± 1.2 SD in
the AKI group and 0.5 ± 0.7 SD in the no AKI group;
P = 0.03).
That there is no significant difference in mean contrast
volume administered to the patients who did and did
not develop AKI (108 mL in the AKI group and 103 mL
in the no-AKI group). There was also no significant dif-
ference between the AKI and no-AKI groups with
regards to percentage of subjects who received greater
than or equal to 150 mL of contrast during TAVR.
Multivariable adjusted associations between pRBC
transfusion and development of post-TAVR AKI
In order to adjust for potential confounders of the asso-
ciation between pRBC transfusion and the development
of AKI after TAVR, a multivariate analysis was per-
formed using a logistic regression model with total num-
ber of pRBCs transfused, nadir Hgb, pre-procedural
estimated glomerular filtration rate (eGFR), and post-
TAVR maximum number of inotropes and vasopressors
used concurrently (Table 2). Total units of pRBC
transfused (OR = 1.67 per unit, 95% CI 1.13–2.47; P =
0.01) remained independently associated with post-
TAVR AKI after adjustments for these other clinical risk
factors. Nadir Hgb was no longer significantly associated
with post-TAVR AKI after adjusting for these additional
variables. Figure 2 further illustrates the finding that
pRBC transfusion rather than peri-procedural nadir Hgb
seems to drive the association with post-TAVR AKI; the
TAVR study cohort is stratified into 4 groups based on if
subjects’ nadir Hgb measured during the TAVR proced-
ure and the 24 h post-TAVR was recorded as < 8 g/dL
versus ≥8 g/dL, and then within these nadir Hgb cat-
egories patients are stratified according to whether they
were or were not transfused pRBCs. AKI development
was not significantly different between the patients who
were transfused pRBC who had a nadir Hgb of < 8 g/dL
and those who were transfused pRBCs and had a nadir
Hgb ≥ 8 g/dL (P = 0.45). Hgb < 8 g/dL was selected since
anesthesiologists typically aim to maintain a Hgb > 7 g/
dL and may consider transfusion in the setting of poten-
tial ongoing procedural blood loss once Hgb falls below
8 g/dL. Post-TAVR maximum number of concurrently
administered inotropes and vasopressors (OR = 2.09 in-
crease for each drug, 95% CI 1.19–3.67; P = 0.01) also in-
dependently associated with post-TAVR AKI in the
multivariable clinical model.
Discussion
AKI is known to be associated with increased risk of
mortality and renal and non-renal morbidities following
TAVR [8, 26]. Despite the less invasive trans-catheter ap-
proach versus open SAVR with CPB, 17.2% of the TAVR
patients in this study developed post-TAVR AKI. Similar
to what has been reported in other TAVR cohorts, most
of the AKI observed in this study was Stage 1 AKI [2,
10, 14, 27–29]. However, even Stage 1 AKI is associated
with increased mortality in ambulatory [8], non-cardiac
surgery [7], cardiac surgery [30] and TAVR patients [27,
28]. Thus, it is important to identify risk factors that can
potentially be modified to mitigate development of AKI
after TAVR.
In this study we found that pRBCs transfusion during
the TAVR procedure or the first 24 h after TAVR signifi-
cantly associates with the occurrence of post-TAVR AKI.
Table 2 Multivariable clinical model for predicting development of in-hospital acute kidney injury (AKI) after trans-catheter aortic
valve replacement (TAVR)
Clinical Variables Odds Ratio 95% Confidence Interval P value
Pre-TAVR eGFR (ml/min/1.73m2) 0.97 0.94 1.00 0.05
Total units of pRBC transfused during procedure and first 24 h post-TAVR (per 1 unit pRBC) 1.67 1.13 2.47 0.01
Nadir hemoglobin during procedure and first 24 h post-procedure (per 1 g/dL increase) 0.88 0.61 1.27 0.50
Maximum number of concurrent inotropes/vasopressors administered during post-TAVR ICU stay
(per each inotrope/vasopressor administered)
2.09 1.19 3.67 0.01
AKI acute kidney injury, TAVR trans-catheter aortic valve replacement, eGFR estimated glomerular filtration rate, pRBC packed red blood cell, ICU intensive care unit
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This was true even after adjusting for other clinical pa-
rameters including pre-TAVR eGFR, nadir measured
peri-procedure Hgb, and post-procedure inotrope and
vasopressor use. Just over one-fourth of our TAVR co-
hort underwent pRBC transfusion. This transfusion rate
is similar to or lower than the rates of pRBC transfusion
that have been reported in other TAVR cohort studies
[10, 14, 29, 31, 32]. Several prior TAVR cohort studies
and a recent meta-analysis have also reported significant
associations between pRBC transfusion and development
of AKI [11, 12, 31, 32]. What differentiates our study
from prior studies is that we concurrently assessed the
associations between intra-procedure hypotension, peri-
procedure anemia, and inotrope/vasopressor usage with
occurrence of post-TAVR AKI. These are additional fac-
tors that could potentially affect perfusion and oxygen
delivery to the kidneys, predisposing to AKI.
There are multiple biologic characteristics of pRBCs
and physiologic responses to transfusion that support
the concept of pRBC transfusion as a putative cause of
AKI. Stored allogenic pRBCs undergo changes in shape
and deformability that can decrease oxygen delivery to
tissues such as the kidney [33, 34]. Plasma levels of the
inflammatory biomarkers bactericidal permeability in-
creasing protein (BPI) and interleukin-6 have also been
reported to be significantly elevated in patients who re-
ceived pRBCs [35]. An in vivo study by Donadee et al
identified storage mediated hemolysis causing impaired
vascular function due to endothelial dysfunction and
vasoconstriction [36]. RBC hemolysis occurs during
pRBC storage and following transfusion can lead to in-
crease in plasma free Hgb and iron which cause dysfunc-
tion of microcirculation [18].
pRBC transfusion has been associated with postopera-
tive AKI or reduced postoperative eGFR in several ob-
servational studies of patients who underwent cardiac
surgery with CPB [16, 17, 37]. These studies found that
preoperative anemia and nadir intraoperative Hgb sig-
nificantly associate with development of AKI [16, 17,
37]. In our study, nadir Hgb did not remain significantly
associated with post-TAVR AKI in the multivariable
analysis. Additional larger prospective studies may be
warranted to assess for interactive influence of peri-
procedural anemia and transfusion in TAVR patients.
To our knowledge no prior study of TAVR patients
has assessed the impact of intra-procedure hypotension
on development of post-TAVR AKI. One cohort study of
213 TAVR patients did assess the occurrence of any
procedural complication that led to severe sustained
hypotension and assessed the association between such
occurrences and development of AKI. They did not ob-
serve an association between such complications and de-
velopment of post-TAVR AKI, but only 10 patients
experienced these complications [32]. We assessed
occurrence of MAP < 60mmHg for greater than or
equal to 5min and also added up the total minutes in all
Fig. 2 Number of patients with post TAVR acute kidney injury (AKI) stratified by packed red blood cell (pRBC) transfusion and periprocedural
anemia (nadir hemoglobin < 8 g/dL versus ≥8 g/dL)
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hypotensive episodes that lasted greater than or equal to
5 consecutive minutes. Neither of these intra-procedure
hypotension variables significantly associated with AKI
in our TAVR cohort. Some have hypothesized that rapid
ventricular pacing during TAVR procedure (i.e. period of
no blood pressure) may be associated with development
of post-TAVR AKI. We did not observe a significant as-
sociation between rapid pacing and development of
post-TAVR AKI, a finding consistent with several other
TAVR studies [14, 32].
We assessed hypotension in the intraoperative period
but not in the postoperative period, as minute-to-minute
post-TAVR blood pressures were not available for our
retrospective study cohort. We did find that post-
procedure inotrope/vasopressor use was independently
associated with development of AKI. Inotrope/vasopres-
sor drug use and its association with AKI has been stud-
ied in the cardiac surgical literature with mixed results.
A study by Haase et al. did not find an association be-
tween vasopressor administration and AKI in patients
undergoing on-pump cardiac surgery [37]. A study by
Magruder et al. investigating patients who developed
AKI following cardiac surgery with CPB showed higher
epinephrine dose on ICU arrival and greater total ad-
ministered dose of epinephrine and norepinephrine in
patients who developed postoperative AKI [38]. Porho-
mayon et al. found a significantly higher incidence of
AKI following vasopressin use during coronary artery
bypass graft surgery with CPB [39].
It is not uncommon to administer inotropes and vaso-
pressor drugs during the TAVR procedure in order to
offset transient effects of anesthesia and/or rapid ven-
tricular pacing. Interestingly, in our study the number of
concurrent inotropes and vasopressors administered
during the TAVR procedure was not associated with de-
velopment of post-TAVR AKI. However, maximum
number of required concurrent inotropes or vasopres-
sors administered after the TAVR procedure was an in-
dependent predictor of AKI. This finding warrants
further prospective study of the impact of post-TAVR
inotropes and vasopressors with a prospectively defined
protocol for how inotropes and vasopressors are dosed
and when multiple inotropes and vasopressors are ad-
ministered. Future study also appears warranted to ad-
dress whether it is post-TAVR hypotension, low cardiac
output, or the vasoconstrictive effects of these drugs
(or a combination of all of these factors) that predis-
poses to AKI.
Iodinated contrast media is administered during TAVR
procedures and is known to have properties that can
cause intense and prolonged vasoconstriction and direct
renal tubular damage [40]. However, awareness of the
potential toxicity of contrast has led to common prac-
tices of pre-procedure hydration, utilization of low
osmolar contrast media and minimizing contrast dose.
Contrast dose did not associate with AKI in our cohort
of TAVR patients. Contrast dose also did not associate
with post-TAVR AKI in several other TAVR cohort stud-
ies [11, 14, 15, 19, 27–29, 31, 32].
Potential limitations of our study should be consid-
ered. It should be recognized that this is a single center
observational study, and additional studies at other cen-
ters should be performed to validate our study’s findings.
The estimated odds ratios for our multivariable model
could be biased by the number of AKI events observed
in our cohort (n = 20), but Vittinghoff and McCulloch
(2007) suggest this potential bias is likely minimal [41].
The association between pRBC transfusion and AKI has
been observed in some but not all previously reported
observational TAVR cohort studies, so our study further
corroborates those studies that have reported a signifi-
cant association between pRBC administration and post-
TAVR AKI [12]. However, future studies are needed to
work out the pathobiologic mechanism(s) of this ob-
served association. In particular, our findings suggest
that anemia may not be a strong modifier of the ob-
served association between pRBC transfusion and post-
TAVR AKI. However, our study is an exploratory retro-
spective assessment, so future larger studies would be
useful to validate this observation. Additionally, nadir
Hgb was determined from available routine clinical care
laboratories. In the setting of bleeding or anticipated
bleeding, clinicians might initiate pRBC transfusion be-
fore a Hgb level is checked, and, thus, true nadir Hgb
might have been missed for some patients. This would
possibly underestimate the association between Hgb and
AKI. Also, this is a retrospective observational study;
therefore a Hgb threshold for initiating pRBCs in clinical
practice is not driven by formal study protocol and may
have some variability from clinician-to-clinician and
patient-to-patient. The significant association between
number of inotrope and vasopressor infusions concur-
rently administered after TAVR and the development of
post-procedure AKI is an intriguing finding, but future
prospective studies are needed to work out the interac-
tions between patients’ hemodynamic profiles as well as
vasoactive drug dosing and the development of AKI in
the post-procedure setting. Finally, many of our patients
are referred to our medical center for TAVR, but their
long-term medical care is continued at outside facilities.
Therefore this retrospective study cannot reliably evalu-
ate mid- and long-term post-TAVR outcomes.
Conclusions
Transfusion of pRBCs but not nadir perioperative Hgb in-
dependently associated with post-TAVR AKI. Maximum
concurrent number of administered inotropes and vaso-
pressors during the post-TAVR period also independently
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associated with the development of post-TAVR AKI. Fu-
ture studies are needed to explore the pathobiological
mechanisms underlying these associations as well as to as-
sess the impact of approaches such as pre-procedure
anemia optimization and restrictive pRBC transfusion
thresholds on the development of post-TAVR AKI.
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